NorthStar Technology to Alleviate Mo-99 Shortage
NorthStar Medical Radioisotopes’ RadioGenix isotope-separation system, which received FDA approval to produce sodium pertechnetate Tc-99m from uranium-free Mo-99, will have the capacity to produce about 10% of radioisotope demand in the US market by the end of this year, and expansion plans for the next several years would enable production for up to two-thirds of the market, said NorthStar Chief Operating Officer Stephen Merrick. The RadioGenix system also could be adapted to produce other therapeutic radioisotopes, such as bismuth-213 and actinium-225, NorthStar says.
Leave A Comment